The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

Lancet. 2006 Aug 5;368(9534):531-6. doi: 10.1016/S0140-6736(06)69162-9.
No abstract available

Publication types

  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active / economics*
  • Cost-Benefit Analysis
  • Female
  • Global Health
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Infections / prevention & control
  • Humans
  • Incidence
  • Male